Redwoods Acquisition Corp. financial data

Symbol
RWOD, RWODR, RWODU, RWODW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1115 Broadway, 12 Th Floor, New York, New York
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 23, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 8.47 % +177%
Debt-to-equity -111 % +77.1%
Return On Equity -1.48 % +97.3%
Return On Assets 0.27 % -86.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.17M shares -41.3%
Common Stock, Shares, Outstanding 3.41M shares 0%
Entity Public Float 56.6M USD -50.2%
Common Stock, Value, Issued 340 USD 0%
Weighted Average Number of Shares Outstanding, Diluted 2.5M shares

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 1.26M USD +52.7%
Operating Income (Loss) -1.32M USD -34.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -74.2K USD -105%
Income Tax Expense (Benefit) 484K USD -80.8%
Net Income (Loss) Attributable to Parent 102K USD -95.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.05K USD
Assets, Current 8.05K USD -97.6%
Assets 19.6M USD -83.6%
Accrued Liabilities, Current 397K USD +183%
Liabilities, Current 2.58M USD -96%
Deferred Income Tax Liabilities, Net 18.1K USD
Liabilities 8.5M USD -87.7%
Retained Earnings (Accumulated Deficit) -7.73M USD -58.4%
Stockholders' Equity Attributable to Parent -7.73M USD -58.4%
Liabilities and Equity 19.6M USD -83.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -377K USD -0.95%
Net Cash Provided by (Used in) Financing Activities 282K USD -44.7%
Net Cash Provided by (Used in) Investing Activities 102M USD
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 3.41M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -223K USD -13079%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.05K USD -93.2%
Deferred Tax Assets, Valuation Allowance 308K USD +175%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 290K USD +775%
Deferred Income Tax Expense (Benefit) 94.8K USD
Deferred Federal Income Tax Expense (Benefit) -257K USD -675%
Additional Paid in Capital 24.7K USD
Current Federal Tax Expense (Benefit) 752K USD +209%